Loading clinical trials...

RECRUITINGPHASE1

F-Tryptophan PET/CT in Human Cancers

A Pilot Study of 1-(2-[18f]Fluoroethyl)-L-Tryptophan PET/CT Imaging In Human Cancers

NCT05556473•Barbara Ann Karmanos Cancer Institute

Summary

Imaging procedures such as 1-(2-\[18F\]FLUOROETHYL)-L-Tryptophan PET/CT in patients with cancers may help doctors assess a patient's response to treatment and help plan the best treatment in the future. The purpose is to see if there can be a better differentiation of tumor and non-tumor tissue where the tumor tissue has a higher uptake of Tryptophan.

Detailed Description

In this research study, we will compare the uptake of the tracer on F-Tryp PET/CT in patients with cancers; specifically, to evaluate whether the tumors show increased tracer uptake as compared to non-tumor tissues, using F-Tryp PET/CT. Additionally, we will evaluate the biodistribution (i.e. track where the tracer has traveled in the body) and radiation dosimetry (i.e., absorbed dose of tracer in tissue). These changes may be compared with results of the physical examination and scans (CT and MRI or standard clinical PET) that are done as part of routine clinical care or as part of other studies. Pictures (images) from the PET scan will be made showing the distribution throughout the body of substances containing a small amount of radioactive material.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Age ≥18 years.
•Targeted lesion (tumor) is at least 1 cm in diameter as shown by clinical imaging.
•Patient is able to lie in the PET/CT scanner for at least 70 minutes while undergoing scanning.
•Women of childbearing potential must not be pregnant or breastfeeding.
•Recent anatomic imaging with visible disease (tumor) for comparison with the PET/CT. .
•Physical exam within 28 days of PET imaging, CBC and Multiphasic (including electrolytes, BUN, creatinine, total bilirubin, AST and ALT) within 14 days.
•Patients must sign an informed consent indicating that they are aware of the investigational nature of this study.
•\- Clinical and MRI diagnosis of an intracranial lesion suspicious for a brain tumor, including gliomas or metastatic brain tumors; primary, residual, or recurrent brain tumors (judged by clinical imaging) will qualify.
•Histopathologically confirmed, well-differentiated metastatic neuroendocrine tumor.
•ECOG performance status of 2 or better.
+5 more criteria

Exclusion Criteria

•Patients who are pregnant or lactating are excluded.
•Severe increased intracranial pressure, status epilepticus, or other symptoms requiring emergency or urgent intervention.
•Tumor surgery or radiation within 1 month prior to the PET scan
•Tumor-directed therapy within 3 months to the area of planned imaging.
•Ongoing treatment with a targeted agent (e.g., sunitinib or everolimus) or receiving cytotoxic chemotherapy (e.g., capecitabine or temozolomide).
•Use of telotristat ethyl (a tryptophan-hydroxylase inhibitor) within one month.
•Recent (within 1 month) tumor resection or radio-chemotherapy (acute/subacute post-treatment inflammatory changes may cause false positive increases on PET).
•Active inflammatory bowel disease (Crohn's or Ulcerative colitis) involving the rectum.

Locations (1)

Karmanos Cancer Institute

Detroit, Michigan, United States

Key Dates

Start Date

September 29, 2022

Primary Completion Date

December 31, 2027

Completion Date

December 31, 2027

Last Updated

January 23, 2026

Enrollment

ESTIMATED participants

Conditions

Intracranial GliomaMetastatic Brain TumorBreast CancerNeuroendocrine TumorsRectal Cancer

Interventions

1-(2-[18F]FLUOROETHYL)-L-Tryptophan

DRUG

Contacts

Csaba Juhasz, M.D., Ph.D

CONTACT

313-966-5136 csaba.juhasz@wayne.edu

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

NCT05245812

Breast CancerHigh Risk of Breast Cancer

View study

RECRUITINGPHASE1

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

NCT04704661

Advanced Breast CarcinomaAdvanced Colon Carcinoma+38 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: January 23, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

F-Tryptophan PET/CT in Human Cancers

Inclusion Criteria

Exclusion Criteria

Safety and Feasibility of Robotic SP Nipple Sparing Mastectomy

Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH Trial

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations

Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer

Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors

Targeted Pediatric High-Grade Glioma Therapy